Np Thyroid 30 (Levothyroxine, Liothyronine)
Brand Names: Np Thyroid 30
Methodology & AI Transparency ⓘ
Np Thyroid 30 (Levothyroxine, Liothyronine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2024-04-30 designates Np Thyroid 30 (NDC 76420-567, 68071-3690, registered by Asclemed USA, Inc.) as a prescription brand-name l-thyroxine formulation of Levothyroxine, Liothyronine.
- 2 Real-world patient consensus: Commercial Np Thyroid 30 monograph (19 ug/1 / 4.5 ug/1 Tablet) cross-indexed with generic Levothyroxine, Liothyronine for therapeutic equivalence review.
- 3 Typical cash cost range: Dispensing cost comparison spans $50.56 mail/discount cash up to $133.98 uninsured retail (federal NADAC $0.5842).
- 4 Top reported side effects / signs: Most commonly reported Np Thyroid 30 (Levothyroxine, Liothyronine) tolerability events: nausea (8%), headache (7.9%), dizziness (6.6%).
Ask our AI Specialists anything about Np Thyroid 30 (Levothyroxine, Liothyronine)
Np Thyroid 30 (Levothyroxine, Liothyronine) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2024-04-30 designates Np Thyroid 30 (NDC 76420-567, 68071-3690, registered by Asclemed USA, Inc.) as a prescription brand-name l-thyroxine formulation of Levothyroxine, Liothyronine. Supplied across 19 ug/1 / 4.5 ug/1 Tablet; Response-guided Levothyroxine, Liothyronine dose modification under follow-up, Np Thyroid 30 is utilized in : NP Thyroid® tablets (thyroid tablets, USP) are indicated: 1.
Clinical pharmacology for Np Thyroid 30 is driven by Levothyroxine, Liothyronine acting within l-thyroxine signaling cascades with class-characteristic hepatorenal disposition. Distributed across 19 ug/1 / 4.5 ug/1 Tablet; Response-guided Levothyroxine, Liothyronine dose modification under follow-up (NDC 76420-567, 68071-3690; registered by Asclemed USA, Inc.), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $50.56 to $133.98.
With Mean elimination half-life of 10 to 23 hours across adult Np Thyroid 30 (Levothyroxine, Liothyronine) dosing residence kinetics and Oral fraction absorbed ranges from 57% to 69% (Np Thyroid 30 (Levothyroxine, Liothyronine) 19) bioavailability, Np Thyroid 30 (Levothyroxine, Liothyronine) undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of np thyroid 30 (levothyroxine, liothyronine) and establishes therapeutic activity over oral tmax achieved within 2 to 3 hours following np thyroid 30 (levothyroxine, liothyronine) ingestion.
Standard adult regimens span 19 ug/1 / 4.5 ug/1 Tablet, Response-guided Levothyroxine, Liothyronine dose modification under follow-up. Prescribers screen specifically against history of severe allergic sensitivity to np thyroid 30 (levothyroxine, liothyronine) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2024-04-30 levothyroxine, liothyronine labeling, while community micro-logs most frequently note nausea (8% of reports), headache (7.9% of reports), dizziness (6.6% of reports).
Prothrombin time and INR stability may fluctuate when Np Thyroid 30 (Levothyroxine, Liothyronine) is added to chronic warfarin regimens.
Verify medication reconciliation lists so Np Thyroid 30 (Levothyroxine, Liothyronine) is not inadvertently duplicated with another l-thyroxine.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Np Thyroid 30 (Levothyroxine, Liothyronine) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2024-04-30 Levothyroxine, Liothyronine labeling
Logged Side-Effect Incidence (13 Reports)
Np Thyroid 30 (Levothyroxine, Liothyronine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Np Thyroid 30 (Levothyroxine, Liothyronine))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Dupilumab response onset, maintenance, and durability in patients with severe: What a 303-Participant Study Found Most patients with CRSwNP achieve clinically meaningful responses to dupilumab by week 16, and most such patients in our study had maintenance and durability of response with continued treatment over time. The Journal of allergy and clinical immunology • 2024-12-15 • Phase III Randomized Trial | N = 303 | 93/100 | PMID 39151476 ↗ |
| New Insights on Impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE: What a 407-Participant Study Found Mepolizumab improves sleep and fatigue in severe CRSwNP, irrespective of comorbid airway disease and BEC, with consistent effects in severe asthma with and without comorbid CRSwNP. Rhinology • 2024-12-01 • Phase III Randomized Trial | N = 407 | 93/100 | PMID 39323188 ↗ |
| Can This Approach Help? Inside the Latest Research on Iron serum levels and iron homeostasis parameters in patients with nosocomial Clinicaltrials.gov registration: NCT03032380. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35025025 ↗ |
| Can This Approach Help? Inside the Latest Research on Global airway disease: mepolizumab simultaneously improves outcomes in severe Our post hoc analysis of the Phase III randomised, gold-standard blind, compared against a dummy pill (placebo), multicentre SYNAPSE study (GSK ID: 205687; NCT03085797) assessed the efficacy of mepolizumab, an... Rhinology • 2025-02-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39660637 ↗ |
| Can This Approach Help? Inside the Latest Research on Mepolizumab improves outcomes in patients with CRSwNP with one or more prior Mepolizumab improves outcomes in patients with CRSwNP with one or multiple prior surgeries; however, may offer greater benefit when initiated after a single surgery. Rhinology • 2026-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42206465 ↗ |
Np Thyroid 30 (Levothyroxine, Liothyronine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5842/unit (~$17.53/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $133.98 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $50.56 / mo | View logs ↓ |
Np Thyroid 30 (Levothyroxine, Liothyronine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Np Thyroid 30 (Levothyroxine, Liothyronine) RxNorm Concept ID | 1724439 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5842 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $133.98 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $50.56 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Np Thyroid 30 (Levothyroxine, Liothyronine) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Np Thyroid 30 (Levothyroxine, Liothyronine) (l-thyroxine) monograph synthesizing RxNorm 1724439, openFDA FAERS signals, and $50.56–$133.98 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Np Thyroid 30 (Levothyroxine, Liothyronine) community threads and patient logs by age, biological sex, dosage, and treatment duration.